Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell-targeting therapies based on its proprietary Alluminox™ platform (photoimmunotherapy), today announced that it will present a poster at the 115th Annual Meeting of the American Association for Cancer Research (AACR 2024) which will take place in San Diego, California, from April 5th to 10th, 2024. The poster presentation will describe Rakuten Medical’s study in a mouse tumor model to evaluate the use of COX-2 inhibition as a potential tool to reduce edema following photoimmunotherapy.
Poster Presentation Overview
- Title: Reduction in photoimmunotherapy-induced edema with COX-2 inhibition: Combatting clinically relevant adverse events without compromising efficacy
- Authors: Gina Ma (Presenter), Myra Gordon, Jason Lapetoda, Abram Lozano, Christopher M. Amantea, Takuya Osada, Amy H. Thorne; Rakuten Medical, Inc.
- Session Title: Inflammation, Host Factors, and Epigenetic Influences on Cancer Development and Treatment
- Date & Time: Monday, April 8th, 2024; 9:00 a.m. – 12:30 p.m. PT
- Location: Poster Section 5; Poster Board Number 13
- Abstract Number: 1415
- Abstract Link: https://www.abstractsonline.com/pp8/#!/20272/presentation/5855
* Rakuten Medical’s therapies based on Alluminox™ platform are investigational outside of Japan.
About Rakuten Medical, Inc.
Rakuten Medical, Inc. is a global biotechnology company developing and commercializing precision, cell targeting therapies based on its proprietary Alluminox™ platform, which, in pre-clinical studies, has been shown to induce rapid and selective cell killing and tumor necrosis. Alluminox therapies have not yet been approved outside of Japan. Rakuten Medical is committed to its mission to conquer cancer by delivering its innovative treatments as quickly as possible to as many patients as possible all over the world. The company has offices in 5 countries, including the United States, where it is headquartered, Japan, Taiwan, Switzerland and India. For more information, visit www.rakuten-med.com.
About Alluminox™ platform
The Alluminox™ platform is an investigational technology platform based on a cancer therapy called photoimmunotherapy, which was developed by Dr. Hisataka Kobayashi and team from the National Cancer Institute in the United States. Rakuten Medical is developing the Alluminox platform as a technology consisting of a drug, device, and other related components. The drug component of the platform consists of a targeting moiety conjugated with one or more dyes leading to selective cell surface binding. The device component consists of a light source that locally illuminates the targeted cells with light to transiently activate the drug. Pre-clinical data have shown that this activation elicits rapid and selective necrosis of targeted cells through a biophysical process that compromises the membrane integrity of the targeted cells. Therapies developed on the Alluminox platform may also result in local and systemic innate and adaptive immune activation due to immunogenic cell death of the targeted cancer cells and/or the removal of targeted immunosuppressive cells within the tumor microenvironment. Outside of Japan, Alluminox therapies have not yet been approved by any regulatory authority.
